Novel transcript, antisense to KCTD21 (ENSG00000288538)

The entry "novel transcript, antisense to KCTD21" (ENSG00000288538) refers to an uncharacterized noncoding RNA transcript. It is not a receptor, enzyme, transporter, or classic drug target, but rather an antisense RNA gene identified as overlapping or opposite the KCTD21 locus. This transcript is classified as noncoding RNA and specifically as an antisense transcript to the KCTD21 gene[1]. Antisense transcripts can regulate their sense counterparts (KCTD21 in this case) via mechanisms such as transcriptional interference, modulating gene expression, or affecting mRNA stability and processing[5][9][13]. However, for this particular transcript (ENSG00000288538), its biological function, disease association, and druggability have not been characterized. Antisense transcripts are widespread throughout the genome and commonly play roles in regulation of gene expression, often through interactions with chromatin or transcription machinery[5][3]. While some antisense RNAs have regulatory functions relevant to development or disease, most "novel transcript, antisense to X" entries represent uncharacterized gene elements discovered via genome-wide sequencing and have no evidence supporting them as therapeutic targets[1][5][9][13]. There is no evidence that ENSG00000288538 functions as a receptor, transporter, enzyme, or any other therapeutic target. It therefore should not be considered a "target" for drug development as of current scientific knowledge. If detailed functional or clinical relevance for ENSG00000288538 is found in future studies, categories such as disease_roles or biomarkers may be updated. At present, this entry is best regarded as an uncharacterized noncoding RNA antisense transcript.

Other names

ENSG00000288538Novel transcript, antisense to KCTD21Antisense to KCTD21